ADVA
11.11.2021 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 3000 OpenFabric1200™ solution to help network operators significantly reduce metro costs. The OTN-based technology enables client services to be groomed into 400Gbit/s wavelengths, maximizing fiber capacity and supporting cost-efficient coherent networks. The latest member of the FSP 3000 OpenFabric™ Series combines open 400Gbit/s pluggable coherent technology with OTN switching on a blade, increasing wavelength efficiency. The open switchponder card can be added to any network without requiring additional adaptors. Specifically engineered for the 400Gbit/s era, the ADVA FSP 3000 OpenFabric1200™ features 1200Gbit/s interface capacity and supports Ethernet and OTN services from 10Gbit/s to 400Gbit/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005220/en/
“The strain on today’s transport infrastructure is growing like never before. Today’s operators need new solutions that can meet rapidly rising data demand while also driving down costs. That’s why we’ve developed our FSP 3000 OpenFabric1200™ . It offers a simple way to dramatically increase fiber efficiency by supporting lower-speed service grooming at the network edge. By deploying OpenFabric1200™ in ring or hub-and-spoke topologies, operators can significantly reduce switching and cross-connect requirements in the core,” said Christoph Glingener, CTO, ADVA. “What’s more, our open Terabit-scale switchponder solution can be easily added to any network.”
The new technology is part of the ADVA FSP 3000 OpenFabric™ Series, a family of switchponders built for maximum openness, flexibility and scale. The OpenFabric1200™ offers OTN switching with the benefits of open CFP2 pluggable coherent interfaces. With Terabit capacity, the new card is the ideal tool for leveraging more value from deployed metro infrastructure and upgrading legacy networks to the latest coherent pluggable technology. The FSP 3000 OpenFabric1200™ can work in multiple operation modes: ADM on a blade, DWDM muxponders, or OTN cross-connect. What’s more, thanks to its open design, client services can be connected directly or via standard OTN-based transponders without the need for any adapters.
“Our FSP 3000 OpenFabric1200™ will be a key tool in tackling skyrocketing bandwidth demand while supporting existing low-speed services. The technology takes our OpenFabric™ concept to the next level, enabling traffic grooming at the edge where it’s most efficient and delivering 1.2Tbit/s interface capacity. It offers the power to adapt to changing traffic demands without a hardware upgrade while simplifying operations and enabling network operators to scale as and when needed,” commented Cornelius Fürst, director, product line management, ADVA. “Our FSP 3000 OpenFabric1200™ is the flexible OTN solution that’s about to switch things up. For metro network operators, our new switchponder opens the door to the benefits of disaggregated environments and the latest pluggable coherent 400Gbit/s technology.”
Watch this video for more information on the FSP 3000 OpenFabric1200™: https://youtu.be/ti101PI1fxw .
Further details are also available in these slides: https://adva.li/fsp-3000-openfabric1200-slides .
A supporting solution brief can be downloaded here: https://adva.li/fsp-3000-openfabric-series-solution-brief .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005220/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom